EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Lung Cancer
About this trial
This is an interventional diagnostic trial for Lung Cancer focused on measuring stage I non-small cell lung cancer, stage II non-small cell lung cancer, stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed or suspected non-small cell lung cancer (NSCLC) If there is no histological or cytological documentation of NSCLC, must have at least a 75% probability of having NSCLC Clinical or pathological stage I-III Patients in whom pre-surgical staging has not definitively established stage IV disease are allowed Tumor mass of ≥ 1.5 cm in maximum diameter must be present on CT scan and must be included in the planned surgical biopsy or resection Must be planning to undergo a surgical staging or treatment procedure (including mediastinoscopy, wedge resection, lobectomy, or pneumonectomy) PATIENT CHARACTERISTICS: Age: 18 and over Performance status: 0-2 Life expectancy: Not specified Hematopoietic: WBC > 2,000/mm^3 Platelet count > 100,000/mm^3 Hepatic: Bilirubin normal Renal: Creatinine normal OR Creatinine clearance ≥ 60 mL/min Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 1 month after study participation Able to hold breath for 27 seconds No allergy to IV contrast dye No history of grade III or IV peripheral neuropathy PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics
Sites / Locations
- Duke Comprehensive Cancer Center
- Veterans Affairs Medical Center - Durham